# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings info...
RBC Capital analyst Gregory Renza initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform rating and anno...
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.
HC Wainwright & Co. analyst Andrew Fein maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price tar...
Piper Sandler analyst Edward Tenthoff maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price ta...
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of ...